Table 2 |
||
|
Association of statin treatment with continuous outcome variables |
||
|
Study |
Outcome |
Parameter estimate and 95% confidence interval |
|
|
||
|
Mortality 2° to COPD |
||
|
|
||
|
Ishida W, et al., Japan, 2007 [23] |
Decreased mortality 2° to COPD in statin users |
Inverse correlation between statin prescriptions dispensed and mortality due COPD by prefecture, p < 0.0001 |
|
|
||
|
Respiratory-related urgent care |
||
|
|
||
|
Keddissi JI, et al., USA, 2007 [26] |
Reduction in respiratory-related emergency-department-visits and/or hospitalizations in statin users |
Incidence of respiratory related urgent care, obstructive spirometry group 0.12 ± 0.29/patient-yrs in statin users versus 0.19 ± 0.32/patient-yrs in control, p = 0.02 |
|
|
||
|
Lung function |
||
|
|
||
|
Keddissi JI, et al., USA, 2007 [26] |
Lower decline in FEV1 and FVC/yr in statin users |
Obstructive spirometry group change in FEV1 +5 ± 207 ml/yr in statin users change in FEV1–86 ± 168 ml/yr in control (p < 0.0001) change in FVC +33 ± 452 ml/yr in statin users change in FVC-150 ± 328 ml/yr in control (p < 0.0001) |
|
|
||
|
Lee T-M, et al., Taiwan, 2008 [19] |
No difference in pulmonary function parameters in statin users |
Pravastatin group: FEV1% at baseline 51 ± 18, at follow-up 55 ± 19 Placebo group: FEV1% at baseline 56 ± 13, at follow-up 55 ± 14, p > 0.05 |
|
|
||
|
Exercise capacity |
||
|
|
||
|
Lee T-M, et al., Taiwan, 2008 [19] |
Improvement in exercise time in statin users |
Pravastatin group: exercise time in s at baseline 599 ± 323, at follow-up 922 ± 328 Placebo group: exercise time in s at baseline 608 ± 273, at follow-up 609 ± 180, p < 0.05 |
|
|
||
|
Borg dyspnea score after exercise tests |
||
|
|
||
|
Lee T-M, et al., Taiwan, 2008 [19] |
Lesser degree of dyspnea after exercise in statin users |
Pravastatin group: Borg dyspnea score at baseline 7.0 ± 0.8, at follow-up 4.0 ± 0.7 Placebo group: Borg dyspnea score at baseline 6.9 ± 0.8, at follow-up 6.9 ± 1.0, p < 0.05 |
|
|
||
|
CRP/IL-6 levels |
||
|
|
||
|
Lee T-M, et al., Taiwan, 2008 [19] |
Decrease in CRP/IL-6 levels in statin users |
Pravastatin group: CRP (mg/l) at baseline 3.94 ± 3.54, at follow-up 3.85 ± 2.56 Placebo group: CRP (mg/l) at baseline 4.06 ± 2.67, at follow-up 2.66 ± 2.49, p < 0.05 |
|
|
||
|
Dobler et al. BMC Pulmonary Medicine 2009 9:32 doi:10.1186/1471-2466-9-32 |
||
